Aung Y Oo, Mahmoud Loubani, Marc W Gerdisch, Joseph Zacharias, Geoffrey M Tsang, Michael J Perchinsky, Robert Carl Hagberg, Mark Joseph, Mohanakrishnan Sathyamoorthy
OBJECTIVES: To assess if warfarin targeted to INR 1.8 (range 1.5-2.0) is safe for all patients with an On-X aortic mechanical valve. METHODS: This prospective, observational registry follows patients receiving warfarin targeted at an INR of 1.8 (range 1.5-2.0) plus daily aspirin (75-100 mg) after On-X aortic valve replacement. The primary end-point is a composite of thromboembolism, valve thrombosis, and major bleeding. Secondary end-points include the individual rates of thromboembolism, valve thrombosis, and major bleeding, as well as the composite in subgroups of home or clinic-monitored INR and risk categorization for thromboembolism...
April 15, 2024: European Journal of Cardio-thoracic Surgery